← Leaderboards
Matthew Lawrence Springer
University Of California San Francisco
$13,274,009
Attributed
$14,536,957
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,536,957 · 12
By mechanism
R01$8,686,261 · 4
R44$2,225,939 · 1
U54$1,640,373 · 2
R21$1,534,706 · 3
R43$299,958 · 1
R03$149,720 · 1
Top collaborators
- Constance M John5 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Neal L Benowitz$31,329,042
- Donald I Abrams$10,076,278
Others in their field
Top investigators on “Rattus”
- Barney Sparrow · Battelle Memorial Institute$76,162,078
- Reshan Fernando · Research Triangle Institute$42,714,061
- Boris Tabakoff · University Of Colorado Denver$35,561,072
- Yasmin L Hurd · Icahn School Of Medicine At Mount Sinai$35,063,410
- Milton D Hejtmancik · Battelle Centers/Pub Hlth Res & Evaluatn$34,625,987
- John Damon Chodera · Sloan-Kettering Inst Can Research$33,543,727
Research focus
RattusBlood VesselsEndotheliumCardiovascular SystemBaseCardiovascular Risk FactorImpairmentMyocardial InfarctionTissuesExposure ToProductionTobaccoTobacco SmokeAcuteLeadCardiovascular HealthCardiovascular DiseasesPhysiologicalEndothelial CellsAdverse EffectsNitric OxideCigaretteResponseMediating
Grant awards (36)
Cardiovascular Effects of Inhalable Tobacco Product Dual Use$807,500
R01 · FY2025 · HL · contact PI
Effects of chronic marijuana use on endothelial function$719,715
R01 · FY2025 · DA · contact PI
Cardiovascular Effects of Inhalable Tobacco Product Dual Use$807,500
R01 · FY2024 · HL · contact PI
Effects of chronic marijuana use on endothelial function$719,615
R01 · FY2024 · DA · contact PI
Effects of chronic marijuana use on endothelial function$701,028
R01 · FY2023 · DA · contact PI
PROJECT 3: CARDIOVASCULAR HEALTH EFFECTS OF EMERGING HEAT-NOT-BURN TOBACCO PRODUCTS$355,092
U54 · FY2022 · HL · contact PI
Validation of NIDA research marijuana as a model for cardiovascular research$362,779
R21 · FY2021 · DA · contact PI
PROJECT 3: CARDIOVASCULAR HEALTH EFFECTS OF EMERGING HEAT-NOT-BURN TOBACCO PRODUCTS$351,740
U54 · FY2021 · HL · contact PI
Upregulation of SARS-CoV-2 receptor and activation proteases by marijuana smoke and e-cigarette aerosols$80,301
R21 · FY2021 · DA · contact PI
PROJECT 3: CARDIOVASCULAR HEALTH EFFECTS OF EMERGING HEAT-NOT-BURN TOBACCO PRODUCTS$326,238
U54 · FY2020 · HL · contact PI
Validation of NIDA research marijuana as a model for cardiovascular research$241,876
R21 · FY2020 · DA · contact PI
PROJECT 3: CARDIOVASCULAR HEALTH EFFECTS OF EMERGING HEAT-NOT-BURN TOBACCO PRODUCTS$321,204
U54 · FY2019 · HL · contact PI
Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction$1,061,083
R44 · FY2018 · AG
Measuring relative cardiovascular health risks of inhaled tobacco products$555,788
R01 · FY2018 · HL · contact PI
PROJECT 3: CARDIOVASCULAR HEALTH EFFECTS OF EMERGING HEAT-NOT-BURN TOBACCO PRODUCTS$286,099
U54 · FY2018 · CA · contact PI
Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction Supplement$131,530
R44 · FY2018 · AG
Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction$808,592
R44 · FY2017 · AG
Measuring relative cardiovascular health risks of inhaled tobacco products$554,950
R01 · FY2017 · HL · contact PI
Measuring relative cardiovascular health risks of inhaled tobacco products$554,138
R01 · FY2016 · HL · contact PI
Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction$224,734
R44 · FY2016 · AG
Measuring relative cardiovascular health risks of inhaled tobacco products$11,662
R01 · FY2016 · HL · contact PI
Measuring relative cardiovascular health risks of inhaled tobacco products$553,145
R01 · FY2015 · HL · contact PI
Measuring relative cardiovascular health risks of inhaled tobacco products$589,154
R01 · FY2014 · HL · contact PI
Protein inhibitor of galectin-3 to limit fibrosis after myocardial infarction$299,958
R43 · FY2013 · HL
Evaluation of harmful effects of cannabis smoke on vascular endothelial function$193,125
R21 · FY2012 · DA · contact PI
The Role of Nitric Oxide Synthase in Circulating Progenitor Cell Function$386,250
R01 · FY2011 · HL · contact PI
Evaluation of harmful effects of cannabis smoke on vascular endothelial function$231,750
R21 · FY2011 · DA · contact PI
Bone marrow cell therapy for cardiac disease: Impact of donor age and infarction$231,750
R21 · FY2011 · HL · contact PI
The Role of Nitric Oxide Synthase in Circulating Progenitor Cell Function$386,250
R01 · FY2010 · HL · contact PI
Bone marrow cell therapy for cardiac disease: Impact of donor age and infarction$193,125
R21 · FY2010 · HL · contact PI
The Role of Nitric Oxide Synthase in Circulating Progenitor Cell Function$386,250
R01 · FY2009 · HL · contact PI
The Role of Nitric Oxide Synthase in Circulating Progenitor Cell Function$182,066
R01 · FY2009 · HL · contact PI
The Role of Nitric Oxide Synthase in Circulating Progenitor Cell Function$386,250
R01 · FY2008 · HL · contact PI
The Role of Nitric Oxide Synthase in Circulating Progenitor Cell Function$385,000
R01 · FY2007 · HL · contact PI
Closed-Chest Cell Injections into Mouse Myocardium Targeted by Ultrasound$73,970
R03 · FY2006 · EB · contact PI
Closed-Chest Cell Injections into Mouse Myocardium Targeted by Ultrasound$75,750
R03 · FY2005 · EB